ImmunoBiology is a biotechnology company that is focused on developing products that could have applications in the treatment of a range of infectious diseases such as meningitis, tuberculosis, influenza and hepatitis C. The company’s technology is based on a the discovery that a group of proteins known as “heat shock proteins” has a pivotal role in controlling the normal immune response to infections. Scancell’s ImmunoBody technology has been licensed for use in non-cancer treatments.
Our experienced team are here to help. Get in touch today.
General enquiries
01942 271 746
enquiries@senecapartners.co.uk
Investors & advisers
01942 295 985
clientteam@senecapartners.co.uk
Press office
0207 071 3932
zpowell@sharecomms.co.uk
Quick enquiry
Specialists in tax-advantaged investments.
Products
Resources
Policies
Copyright © 2022 Seneca Partners Limited. All rights reserved.
Seneca Partners Limited (Company No. 07196273) is Authorised and Regulated by the Financial Conduct Authority (FRN 583361).
Seneca Partners Limited’s registered office is at 9 The Parks, Haydock, WA12 0JQ.
The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.
Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.
Please confirm that you understand this warning and wish to proceed.